The Korean journal of internal medicine

  • 제25권4호
  • /
  • Pages.399-407
  • /
  • 2010
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Microarray Analysis of Papillary Thyroid Cancers in Korean

  • Kim, Hyun-Sook (Department of Internal Medicine, Catholic University of Daegu School of Medicine) ;
  • Kim, Do-Hyung (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Kim, Ji-Yeon (Department of Internal Medicine, Catholic University of Daegu School of Medicine) ;
  • Jeoung, Nam-Ho (Department of Fundamental Medical and Pharmaceutical Sciences, Catholic University of Daegu) ;
  • Lee, In-Kyu (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Bong, Jin-Gu (Department of General Surgery, Catholic University of Daegu School of Medicine) ;
  • Jung, Eui-Dal (Department of Internal Medicine, Catholic University of Daegu School of Medicine)
  • 투고 : 2010.05.18
  • 심사 : 2010.09.15
  • 발행 : 2010.12.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: Papillary thyroid cancer (PTC) is the most common malignancy of the thyroid gland. It involves several molecular mechanisms. The BRAF V600E mutation has been identified as the most common genetic abnormality in PTC. Moreover, it is known to be more prevalent in Korean PTC patients than in patients from other countries. We investigated distinct genetic profiles in Korean PTC through cDNA microarray analysis. Methods: Transcriptional profiles of five PTC samples and five paired normal thyroid tissue samples were generated using cDNA microarrays. The tumors were genotyped for BRAF mutations. The results of the cDNA microarray gene expression analysis were confirmed by real-time PCR and immunohistochemistry analysis of 35 PTC patients. Results: Four of the five patients whose PTC tissues were subjected to microarray analysis were found to carry the BRAF V600E mutation. Microarrays analysis of the five PTC tissue samples showed the expression of 96 genes to be increased and that of 16 genes decreased. Real-time reverse transcription-polymerase chain reaction (RT-PCR) confirmed increased expression of SLC34A2, TM7SF4, COMP, KLK7, and KCNJ2 and decreased expression of FOXA2, SLC4A4, LYVE-1, and TFCP2L1 in PTC compared with normal tissue. Of these genes, TFCP2L1, LYVE-1, and KLK7 were previously unidentified in PTC microarray analysis. Notably, Foxa2 activity in PTC was reduced, as shown by its cytoplasmic localization, in immunohistochemical analyses. Conclusions: These findings demonstrate both similarities and differences between our results and previous reports. In Korean cases of PTC, Foxa2 activity was reduced with its cytoplasmic accumulation. Further studies are needed to confirm the relationship between FOXA2 and BRAF mutations in Korean cases of PTC.

키워드

과제정보

연구 과제 주관 기관 : National Research Foundation

참고문헌

  1. Lind P, Langsteger W, Molnar M, Gallowitsch HJ, Mikosch P, Gomez I. Epidemiology of thyroid diseases in iodine sufficiency. Thyroid 1998;8:1179-1183. https://doi.org/10.1089/thy.1998.8.1179
  2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998;83:2638-2648. https://doi.org/10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1
  3. Gimm O. Thyroid cancer. Cancer Lett 2001;163:143-156. https://doi.org/10.1016/S0304-3835(00)00697-2
  4. Neff RL, Farrar WB, Kloos RT, Burman KD. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 2008;37:525-538, xi. https://doi.org/10.1016/j.ecl.2008.02.003
  5. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130:1028-1034. https://doi.org/10.1067/msy.2001.118266
  6. Kinder BK. Well differentiated thyroid cancer. Curr Opin Oncol 2003;15:71-77. https://doi.org/10.1097/00001622-200301000-00011
  7. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292-306. https://doi.org/10.1038/nrc1836
  8. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004;45:818-821. https://doi.org/10.3349/ymj.2004.45.5.818
  9. Slough CM, Randolph GW. Workup of well-differentiated thyroid carcinoma. Cancer Control 2006;13:99-105. https://doi.org/10.1177/107327480601300203
  10. Amrikachi M, Ramzy I, Rubenfeld S, Wheeler TM. Accuracy of fine-needle aspiration of thyroid. Arch Pathol Lab Med 2001;125:484-488.
  11. Goellner JR, Gharib H, Grant CS, Johnson DA. Fine needle aspiration cytology of the thyroid, 1980 to 1986. Acta Cytol 1987;31:587-590.
  12. Griffith OL, Melck A, Jones SJ, Wiseman SM. Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol 2006;24:5043-5051. https://doi.org/10.1200/JCO.2006.06.7330
  13. Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 2005;24:6646-6656. https://doi.org/10.1038/sj.onc.1208822
  14. Eszlinger M, Krohn K, Kukulska A, Jarzab B, Paschke R. Perspectives and limitations of microarray-based gene expression profiling of thyroid tumors. Endocr Rev 2007;28:322-338. https://doi.org/10.1210/er.2006-0047
  15. Hartgers FC, Vissers JL, Looman MW, et al. DC-STAMP, a novel multimembrane-spanning molecule preferentially expressed by dendritic cells. Eur J Immunol 2000;30:3585-3590. https://doi.org/10.1002/1521-4141(200012)30:12<3585::AID-IMMU3585>3.0.CO;2-Y
  16. Yagi M, Miyamoto T, Sawatani Y, et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 2005;202:345-351. https://doi.org/10.1084/jem.20050645
  17. Lee KY, Huang SM, Li S, Kim JM. Identification of differentially expressed genes in papillary thyroid cancers. Yonsei Med J 2009;50:60-67. https://doi.org/10.3349/ymj.2009.50.1.60
  18. Galeza-Kulik M, Zebracka J, Szpak-Ulczok S, et al. Expression of selected genes involved in transport of ions in papillary thyroid carcinoma. Endokrynol Pol 2006;57(Suppl A):26-31.
  19. Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004;2:257-280.
  20. Paliouras M, Borgono C, Diamandis EP. Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007;249:61-79. https://doi.org/10.1016/j.canlet.2006.12.018
  21. Talieri M, Mathioudaki K, Prezas P, et al. Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. Thromb Haemost 2009;101:741-747.
  22. Arden KC. Multiple roles of FOXO transcription factors in mammalian cells point to multiple roles in cancer. Exp Gerontol 2006;41:709-717. https://doi.org/10.1016/j.exger.2006.05.015
  23. Reagan-Shaw S, Ahmad N. The role of Forkhead-box Class O (FoxO) transcription factors in cancer: a target for the management of cancer. Toxicol Appl Pharmacol 2007;224:360-368. https://doi.org/10.1016/j.taap.2006.12.003
  24. Karger S, Weidinger C, Krause K, et al. FOXO3a: a novel player in thyroid carcinogenesis? Endocr Relat Cancer 2009;16:189-199.
  25. Akagi T, Luong QT, Gui D, et al. Induction of sodium iodide symporter gene and molecular characterisation of $HNF_3$ $beta/FoxA_2$, TTF-1 and C/EBP beta in thyroid carcinoma cells. Br J Cancer 2008;99:781-788. https://doi.org/10.1038/sj.bjc.6604544

피인용 문헌

  1. Increased T-Allele Frequency of 677 C&gt;T Polymorphism in the Methylenetetrahydrofolate Reductase Gene in Differentiated Thyroid Carcinoma vol.16, pp.7, 2010, https://doi.org/10.1089/gtmb.2011.0347
  2. Gene expression profiling of papillary thyroid carcinomas in Korean patients by oligonucleotide microarrays vol.82, pp.5, 2010, https://doi.org/10.4174/jkss.2012.82.5.271
  3. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress vol.485, pp.7400, 2010, https://doi.org/10.1038/nature11066
  4. The Divergence, Actions, Roles, and Relatives of Sodium-Coupled Bicarbonate Transporters vol.93, pp.2, 2010, https://doi.org/10.1152/physrev.00023.2012
  5. Knockdown of the Sodium-Dependent Phosphate Co-Transporter 2b (NPT2b) Suppresses Lung Tumorigenesis vol.8, pp.10, 2010, https://doi.org/10.1371/journal.pone.0077121
  6. RNA Sequencing Identifies Multiple Fusion Transcripts, Differentially Expressed Genes, and Reduced Expression of Immune Function Genes in BRAF (V600E) Mutant vs BRAF Wild-Type Papillary Thyroid Carcin vol.99, pp.2, 2010, https://doi.org/10.1210/jc.2013-2792
  7. Regulation and roles of bicarbonate transporters in cancer vol.5, pp.None, 2014, https://doi.org/10.3389/fphys.2014.00130
  8. Effect of BRAF mutational status on expression profiles in conventional papillary thyroid carcinomas vol.16, pp.suppl1, 2015, https://doi.org/10.1186/1471-2164-16-s1-s6
  9. Comparison of microarray expression profiles between follicular variant of papillary thyroid carcinomas and follicular adenomas of the thyroid vol.16, pp.suppl1, 2010, https://doi.org/10.1186/1471-2164-16-s1-s7
  10. Biological effects of inorganic phosphate: potential signal of toxicity vol.40, pp.1, 2015, https://doi.org/10.2131/jts.40.55
  11. Microarray technology to investigate genes associated with papillary thyroid carcinoma vol.11, pp.5, 2010, https://doi.org/10.3892/mmr.2015.3180
  12. Gene expression profiling in undifferentiated thyroid carcinoma induced by high-dose radiation vol.57, pp.3, 2016, https://doi.org/10.1093/jrr/rrw002
  13. A robust biomarker of differential correlations improves the diagnosis of cytologically indeterminate thyroid cancers vol.37, pp.5, 2016, https://doi.org/10.3892/ijmm.2016.2534
  14. Anoctamin5 regulates cell migration and invasion in thyroid cancer vol.51, pp.4, 2017, https://doi.org/10.3892/ijo.2017.4113
  15. Transcriptomic comparison of primary bovine horn core carcinoma culture and parental tissue at early stage vol.10, pp.1, 2010, https://doi.org/10.14202/vetworld.2017.38-55
  16. Aberrant expression of kallikrein‐related peptidase 7 is correlated with human melanoma aggressiveness by stimulating cell migration and invasion vol.11, pp.10, 2010, https://doi.org/10.1002/1878-0261.12103
  17. Kallikreins Stepwise Scoring Reveals Three Subtypes of Papillary Thyroid Cancer with Prognostic Implications vol.28, pp.5, 2010, https://doi.org/10.1089/thy.2017.0501
  18. Identification of Key Pathways and Genes in Anaplastic Thyroid Carcinoma via Integrated Bioinformatics Analysis vol.24, pp.None, 2018, https://doi.org/10.12659/msm.910088
  19. Identification of potential functional genes in papillary thyroid cancer by co-expression network analysis vol.16, pp.4, 2010, https://doi.org/10.3892/ol.2018.9306
  20. Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types vol.9, pp.25, 2010, https://doi.org/10.18632/oncotarget.24947
  21. Identification and bioinformatics analysis of overlapping differentially expressed genes in depression, papillary thyroid cancer and uterine fibroids vol.15, pp.6, 2010, https://doi.org/10.3892/etm.2018.6023
  22. Long noncoding RNA NEAT1 regulate papillary thyroid cancer progression by modulating miR‐129‐5p/KLK7 expression vol.233, pp.10, 2018, https://doi.org/10.1002/jcp.26425
  23. Role of differentially expressed genes and long non‐coding RNAs in papillary thyroid carcinoma diagnosis, progression, and prognosis vol.119, pp.10, 2010, https://doi.org/10.1002/jcb.26836
  24. Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations vol.16, pp.3, 2019, https://doi.org/10.7150/ijms.29935
  25. Network Analyses of Integrated Differentially Expressed Genes in Papillary Thyroid Carcinoma to Identify Characteristic Genes vol.10, pp.1, 2019, https://doi.org/10.3390/genes10010045
  26. Gene expression profiling identifies potential molecular markers of papillary thyroid carcinoma vol.24, pp.1, 2019, https://doi.org/10.3233/cbm-181758
  27. LncRNA FOXD2‐AS1 accelerates the papillary thyroid cancer progression through regulating the miR‐485‐5p/KLK7 axis vol.120, pp.5, 2010, https://doi.org/10.1002/jcb.28072
  28. Gene Expression Patterns Unveil New Insights in Papillary Thyroid Cancer vol.55, pp.8, 2019, https://doi.org/10.3390/medicina55080500
  29. MiR-4500 Regulates PLXNC1 and Inhibits Papillary Thyroid Cancer Progression vol.10, pp.4, 2010, https://doi.org/10.1007/s12672-019-00366-1
  30. CircHACE1 functions as a competitive endogenous RNA to curb differentiated thyroid cancer progression by upregulating Tfcp2L1 through adsorbing miR-346 vol.68, pp.8, 2010, https://doi.org/10.1507/endocrj.ej20-0806
  31. Modulating phosphate consumption, a novel therapeutic approach for the control of cancer cell proliferation and tumorigenesis vol.183, pp.None, 2021, https://doi.org/10.1016/j.bcp.2020.114305
  32. Evaluation of the Prognostic Value of Solute Carrier Family 34 Member 2 “SLC34A2” in Papillary Thyroid Carcinoma: An Immunohistochemical Study vol.2021, pp.None, 2021, https://doi.org/10.1155/2021/3198555
  33. Interference with KCNJ2 inhibits proliferation, migration and EMT progression of apillary thyroid carcinoma cells by upregulating GNG2 expression vol.24, pp.3, 2021, https://doi.org/10.3892/mmr.2021.12261
  34. Heavy Metals in the Environment and Thyroid Cancer vol.13, pp.16, 2010, https://doi.org/10.3390/cancers13164052
  35. Systems biomarkers for papillary thyroid cancer prognosis and treatment through multi-omics networks vol.715, pp.None, 2022, https://doi.org/10.1016/j.abb.2021.109085
  36. Low expression of TFF3 in papillary thyroid carcinoma may correlate with poor prognosis but high immune cell infiltration vol.18, pp.3, 2010, https://doi.org/10.2217/fon-2020-1183